Last update 18 Nov 2024

I-Mab Biopharma US Ltd.

Subsidiary Company|
2018|
Maryland, United States

Overview

Tags

Neoplasms
Digestive System Disorders
Hemic and Lymphatic Diseases
Monoclonal antibody
Bispecific antibody
Fusion protein

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms5
Endocrinology and Metabolic Disease4
Hemic and Lymphatic Diseases3
Immune System Diseases3
Nervous System Diseases2
Infectious Diseases2
Top 5 Drug TypeCount
Monoclonal antibody3
Bispecific antibody1
Fusion protein1
Top 5 TargetCount
4-1BB x CLDN18.21
CD47(Cluster of differentiation 47)1
PD-1(Programmed cell death protein 1)1
CD73(5-nucleotidase)1
IL-7Rα(Interleukin-7 receptor subunit alpha)1

Related

5
Drugs associated with I-Mab Biopharma US Ltd.
Pembrolizumab
Target
PD-1
Mechanism
PD-1 inhibitors
Active Org.
National Cancer InstituteNational Cancer Institute [+84]
Originator Org.
Merck & Co., Inc.Merck & Co., Inc.
Active Indication
Malignant Pleural Mesothelioma [+507]
Inactive Indication
Acute lymphoblastic leukemia recurrent [+70]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date04 Sep 2014
Lemzoparlimab
Target
CD47
Mechanism
CD47 inhibitors
Active Org.
I-Mab Biopharma US Ltd. [+2]
Originator Org.
I-MAB Biopharma (Shanghai) Co., Ltd.I-MAB Biopharma (Shanghai) Co., Ltd.
Active Indication
Myelodysplastic Syndromes [+6]
Inactive Indication
Bone Marrow Neoplasms [+2]
Drug Highest PhasePhase 3
First Approval Ctry. / Loc.-
First Approval Date-
Uliledlimab
Target
CD73
Mechanism
CD73 inhibitors
Active Org.
I-Mab Biopharma US Ltd. [+2]
Originator Org.
I-MAB Biopharma (Shanghai) Co., Ltd.I-MAB Biopharma (Shanghai) Co., Ltd.
Active Indication
Non-Small Cell Lung Cancer [+8]
Inactive Indication
Neoplasm Metastasis
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
6
Clinical Trials associated with I-Mab Biopharma US Ltd.
CTR20212803 / RecruitingPhase 2
评价TJ107与帕博利珠单抗注射液联合治疗在局部晚期或转移性实体瘤患者中的安全性和耐受性以及初步疗效的多中心、开放、探索性II期临床研究
[Translation] A multicenter, open, exploratory Phase II clinical study to evaluate the safety, tolerability and preliminary efficacy of TJ107 combined with pembrolizumab injection in patients with locally advanced or metastatic solid tumors
NCT05001347 / CompletedPhase 2
A Phase 2 Clinical Study of TJ004309 in Combination With Atezolizumab (TECENTRIQ®) in Patients With Advanced or Metastatic Ovarian Cancers and Selected Advanced Solid Tumors
NCT04900818 / RecruitingPhase 1
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
100 Clinical Results associated with I-Mab Biopharma US Ltd.
Login to view more data
0 Patents (Medical) associated with I-Mab Biopharma US Ltd.
Login to view more data
100 Deals associated with I-Mab Biopharma US Ltd.
Login to view more data
100 Translational Medicine associated with I-Mab Biopharma US Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1
3
2
Phase 2
Other
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free